Naproxen and Piqray 300MG Daily Dose
Determining the interaction of Naproxen and Piqray 300MG Daily Dose and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with alpelisib may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 2C9, such as warfarin. The proposed mechanism, based on in vitro data, is increased clearance due to alpelisib-mediated induction of CYP450 2C9. MANAGEMENT: Patient monitoring is recommended if alpelisib is used concomitantly with drugs that are substrates of CYP450 2C9, particularly those with a narrow therapeutic range. The potential for diminished therapeutic effects should be considered when alpelisib is prescribed in combination with drugs that are CYP450 2C9 substrates. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever alpelisib is added to or withdrawn from therapy with these drugs. An alternative agent with no or minimal CYP450 2C9-inducing activity may also be considered. References "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.
Professional:MONITOR: Coadministration with alpelisib may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 2C9, such as warfarin. The proposed mechanism, based on in vitro data, is increased clearance due to alpelisib-mediated induction of CYP450 2C9.
MANAGEMENT: Patient monitoring is recommended if alpelisib is used concomitantly with drugs that are substrates of CYP450 2C9, particularly those with a narrow therapeutic range. The potential for diminished therapeutic effects should be considered when alpelisib is prescribed in combination with drugs that are CYP450 2C9 substrates. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever alpelisib is added to or withdrawn from therapy with these drugs. An alternative agent with no or minimal CYP450 2C9-inducing activity may also be considered.
- "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.
Generic Name: naproxen
Brand name: Aleve, EC-Naprosyn, Flanax Pain Reliever, Midol Extended Relief, Naprelan, Naprosyn, Anaprox, Anaprox-DS, Naproxen Sodium, Aleve Caplet, Aleve Gelcap, Aleve Easy Open Arthritis, Naprelan 375, Naprelan 500, Flanax
Synonyms: n.a.
Generic Name: alpelisib
Brand name: Piqray
Synonyms: Alpelisib
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Naproxen-Pirbuterol Inhalation
- Naproxen-Pirfenidone
- Naproxen-Pirmella 1/35
- Naproxen-Pirmella 7/7/7
- Naproxen-Piroxicam
- Naproxen-Piroxicam (Systemic)
- Piqray 300MG Daily Dose-Naproxen and Diphenhydramine
- Piqray 300MG Daily Dose-Naproxen and Esomeprazole
- Piqray 300MG Daily Dose-Naproxen and pseudoephedrine
- Piqray 300MG Daily Dose-Naproxen CR Tablets
- Piqray 300MG Daily Dose-Naproxen Delayed Release
- Piqray 300MG Daily Dose-Naproxen Modified-Release Tablets